Neuromuscular junction denervation and terminal Schwann cell loss in the hTDP-43 overexpression mouse model of amyotrophic lateral sclerosis
- PMID: 37465879
- DOI: 10.1111/nan.12925
Neuromuscular junction denervation and terminal Schwann cell loss in the hTDP-43 overexpression mouse model of amyotrophic lateral sclerosis
Abstract
Aims: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with complex aetiology. Despite evidence of neuromuscular junction (NMJ) denervation and 'dying-back' pathology in models of SOD1-dependent ALS, evidence in other genetic forms of ALS is limited by a lack of suitable animal models. TDP-43, a key mediator protein in ALS, is overexpressed in neurons in Thy1-hTDP-43WT mice. We therefore aimed to comprehensively analyse NMJ pathology in this model of ALS.
Methods: Expression of TDP-43 was assessed via western blotting. Immunohistochemistry techniques, alongside NMJ-morph quantification, were used to analyse motor neuron number, NMJ denervation status and terminal Schwann cell morphology.
Results: We present a time course of progressive, region-specific motor neuron pathology in Thy1-hTDP-43WT mice. Thy1-driven hTDP-43 expression increased steadily, correlating with developing hindlimb motor weakness and associated motor neuron loss in the spinal cord with a median survival of 21 days. Pronounced NMJ denervation was observed in hindlimb muscles, mild denervation in cranial muscles but no evidence of denervation in either forelimb or trunk muscles. NMJ pathology was restricted to motor nerve terminals, with denervation following the same time course as motor neuron loss. Terminal Schwann cells were lost from NMJs in hindlimb muscles, directly correlating with denervation status.
Conclusions: Thy1-hTDP-43WT mice represent a severe model of ALS, with NMJ pathology/denervation of distal muscles and motor neuron loss, as observed in ALS patients. This model therefore provides an ideal platform to investigate mechanisms of dying-back pathology, as well as NMJ-targeting disease-modifying therapies in ALS.
Keywords: NMJ denervation; TDP-43 proteinopathies; amyotrophic lateral sclerosis; motor neuron disease; transgenic mouse.
© 2023 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.
Similar articles
-
Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.J Chem Neuroanat. 2016 Oct;76(Pt A):35-47. doi: 10.1016/j.jchemneu.2016.03.003. Epub 2016 Mar 30. J Chem Neuroanat. 2016. PMID: 27038603
-
Properties of Glial Cell at the Neuromuscular Junction Are Incompatible with Synaptic Repair in the SOD1G37R ALS Mouse Model.J Neurosci. 2020 Sep 30;40(40):7759-7777. doi: 10.1523/JNEUROSCI.1748-18.2020. Epub 2020 Aug 28. J Neurosci. 2020. PMID: 32859714 Free PMC article.
-
AAV-NRIP gene therapy ameliorates motor neuron degeneration and muscle atrophy in ALS model mice.Skelet Muscle. 2024 Jul 24;14(1):17. doi: 10.1186/s13395-024-00349-z. Skelet Muscle. 2024. PMID: 39044305 Free PMC article.
-
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis.Transl Neurodegener. 2022 Dec 27;11(1):56. doi: 10.1186/s40035-022-00331-z. Transl Neurodegener. 2022. PMID: 36575535 Free PMC article. Review.
-
Small junction, big problems: Neuromuscular junction pathology in mouse models of amyotrophic lateral sclerosis (ALS).J Anat. 2022 Nov;241(5):1089-1107. doi: 10.1111/joa.13463. Epub 2021 Jun 7. J Anat. 2022. PMID: 34101196 Free PMC article. Review.
Cited by
-
Muscle-specific kinase levels in blood are an early diagnostic biomarker for SOD1-93A mouse model of ALS.Front Neurol. 2025 Apr 28;16:1556120. doi: 10.3389/fneur.2025.1556120. eCollection 2025. Front Neurol. 2025. PMID: 40356623 Free PMC article.
-
Treating amyotrophic lateral sclerosis with allogeneic Schwann cell-derived exosomal vesicles: a case report.Neural Regen Res. 2025 Apr 1;20(4):1207-1216. doi: 10.4103/NRR.NRR-D-23-01815. Epub 2024 Apr 3. Neural Regen Res. 2025. PMID: 38922880 Free PMC article.
-
Schwann Cells in Neuromuscular Disorders: A Spotlight on Amyotrophic Lateral Sclerosis.Cells. 2025 Jan 3;14(1):47. doi: 10.3390/cells14010047. Cells. 2025. PMID: 39791748 Free PMC article. Review.
-
Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses.Cells. 2025 May 8;14(10):680. doi: 10.3390/cells14100680. Cells. 2025. PMID: 40422183 Free PMC article. Review.
References
REFERENCES
-
- van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098. doi:10.1016/S0140-6736(17)31287-4
-
- Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540-549. doi:10.1136/jnnp-2016-315018
-
- Sleigh JN, Tosolini AP, Gordon D, et al. Mice carrying ALS mutant TDP-43, but not mutant FUS, display in vivo defects in axonal transport of signaling endosomes. Cell Rep. 2020;30(11):3655-3662.e2. doi:10.1016/j.celrep.2020.02.078
-
- Arnold ES, Ling SC, Huelga SC, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S a. 2013;110(8):E736-E745. doi:10.1073/pnas.1222809110
-
- Neumann M, Sampathu DM, Kwong L, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (80-). 2006;314(5796):130-133. doi:10.1126/science.1134108
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous